What’s New

***PRESS RELEASE*** Health Plans Nationwide Reject 43 percent of Claims for High Cholesterol Treatment

National health plan report card analyzes PCSK9 inhibitor claims for managed care organizations  WASHINGTON – The Institute for Patient Access released a new National Health

Read More

Health Plan Report Cards Reveal High Rejection Rate for Cholesterol Meds

Rejection is never pleasant.  But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.

Read More

***PRESS RELEASE*** Biologics Prescribers Collaborative Releases New White Paper: The State of Biosimilars Policy

White paper addresses current policy issues impacting biosimilars including naming, interchangeability, and labeling and reimbursement policies   WASHINGTON – Today the Biologics Prescribers Collaborative (BPC), a project

Read More

***MEDIA ADVISORY*** Biosimilars Policy Framework Briefing to Discuss Impact on Prescribing, Reimbursement and Use

WASHINGTON – Tomorrow, April 27, the Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, will host a congressional briefing on Capitol Hill

Read More

Tubing Mix-ups Pose New Dangers for Infants

Robin Rogers was 35 weeks pregnant when she began to suffer from significant vomiting and dehydration. She was admitted to the hospital near her home

Read More

Feedback on ICER’s Dupilumab and Crisaborole for Atopic Dermatitis- Effectiveness and Value Draft Evidence Report

April 17, 2017 Submitted electronically to: [email protected] Steven D. Pearson, MD, President Institute for Clinical and Economic Review Two Liberty Square, Ninth Floor Boston, MA

Read More

Keeping Asthma Medication within Patients’ Reach

A new bureaucratic obstacle could make it even harder for asthma patients to get the medicine they need. For several years now, high cost-sharing has

Read More

***PRESS RELEASE*** Biosimilars Policy Framework Briefing to Discuss Impact on Prescribing, Reimbursement and Use

Congressional briefing will explore naming, interchangeability, and labeling; reimbursement policies and the Biosimilar User Fee Act  WASHINGTON – On Thursday, April 27 the Biologics Prescribers Collaborative

Read More

Trials Data Raises Hopes in Cystic Fibrosis Community

Promising clinical trials data has excited patients with cystic fibrosis and their families.  But will access barriers dash their hopes for more and better treatment

Read More

***PRESS RELEASE*** New Policy Paper Offers Physician’s Perspective on Oncology Value Models

Institute for Patient Access paper explains value models must serve as tools, not replacements, for physician decision-making  WASHINGTON – The Institute for Patient Access released a

Read More
Back to Top